11 May Prolaris Score Predicts Prostate Cancer Survival and Recurrence in Low Risk Disease
MedicalResearch.com Interview with:
Dr. Michael K. Brawer, MD
Northwest Prostate Institute
MedicalResearch.com: What is the background for this study? What are the main findings?
Dr. Brawer: Prolaris (Cell Cycle Progression Test) is a prostate-cancer prognostic genetic tests that determines how aggressive is a patient’s cancer. The goal is to reduce the over treatment of tumors that are likely to be harmless while still spotting those that are lethal. Our key study at AUA (American Urological Society) is a meta-analysis of 440 prostate cancer patients with a Gleason score less than or equal to 6 who were tested with Prolaris.
MedicalResearch.com: What should readers take away from your report?
Dr. Brawer: The data showed that Prolaris is the best significant predictor of the most meaningful oncologic outcomes of survival and recurrence in low-risk disease when combined with standard pathological analysis. Patients with high Prolaris scores had three times the risk of 10 year disease specific mortality and almost eight times the risk of biochemical recurrence compared to patients with low Prolaris scores.
For more study results view the study poster at: https://s3.amazonaws.com/myriad-web/myriad.com/media-kits/AUA+2016_Bishoff_Gleason.pdf
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Dr. Brawer: Prolaris has been validated in patients with low, intermediate and high-risk prostate cancers. All men with localized prostate cancer are candidates for the Prolaris test.
MedicalResearch.com: Is there anything else you would like to add?
Dr. Brawer: Patients should talk with their doctor if they have questions. Also, more information is available at www.prolaris.com.
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
Citation: Abstract presented at the 2016 AUA Meeting May 2016
The CCP score provides significant prognostic information in Gleason score < 7 patients
Authors: Jay Bishoff , Stephen Freedland, Thorsten Schlomm, Julia Reid, Michael Brawer,
Steven Stone, Jack Cuzick
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.